Drew Lewis

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink et al. · The Lancet Infectious Diseases · 2023 · 238 citations

Antimicrobial Susceptibility, Antimicrobial Stewardship, Antibiotics +12

Single-Dose Azithromycin Microspheres vs Clarithromycin Extended Release for the Treatment of Mild-to-Moderate Community-Acquired Pneumonia in Adults

Margaret Drehobl, María Cristina De Salvo, Drew Lewis et al. · CHEST Journal · 2005 · 70 citations

Clarithromycin Extended Release, Antibiotics, Mild-to-moderate Community-acquired Pneumonia +8

Novel, Single-Dose Microsphere Formulation of Azithromycin versus 7-Day Levofloxacin Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults

Joseph D'Ignazio, Marco A. Camere, Drew Lewis et al. · Antimicrobial Agents and Chemotherapy · 2005 · 68 citations · Full text

Moderate Community-acquired Pneumonia, Pharmacotherapy, Antimicrobial Chemotherapy +16

Cost impact of hydroxocobalamin in the treatment of patients with known or suspected cyanide poisoning due to smoke inhalation from closed-space fires

Kafi N. Sanders, Jyoti Aggarwal, Jennifer Stephens et al. · Burns · 2021 · 11 citations · Full text